Allergan Inc. will acquire dermatology company Vicept Therapeutics Inc. in a deal worth up to $275 million. Malvern, Pa..-based Vicept's lead product, V-101, is in development for rosacea and has showed positive results in Phase II trials. The acquisition will beef up Allergan's range of dermatology products, which includes Tazorac (tazarotene) and Botox (onabotulinumtoxinA).